Reversal of Tenecteplase (TNK)
Key Pharmacologic Characteristics
- The American Heart Association notes that tenecteplase is a genetically engineered tissue plasminogen activator with a terminal half-life of 65-132 minutes and initial disposition half-life of 17-24 minutes, meaning the drug's fibrinolytic effects dissipate relatively quickly after administration 1
Management of Major Bleeding Complications
- The American College of Cardiology recommends that for life-threatening bleeding complications, management relies on supportive care, discontinuation of the drug, and administration of antifibrinolytic agents (cryoprecipitate, fresh frozen plasma, or tranexamic acid) 2
- The European Society of Cardiology suggests assessing the bleeding source and severity, with intracranial hemorrhage occurring in approximately 1-2% of patients, while major non-cerebral bleeding occurs in 4-6% 2, 3
- The American Heart Association advises obtaining emergency imaging for suspected intracranial hemorrhage 2
- The American College of Cardiology recommends administering cryoprecipitate (10 units) or fresh frozen plasma (2-4 units) to replace fibrinogen and clotting factors depleted by fibrinolysis 2
- The European Society of Cardiology suggests considering tranexamic acid (1 gram IV over 10 minutes) as an antifibrinolytic agent to inhibit plasminogen activation and stabilize clot formation 2
- The American College of Cardiology notes that platelet transfusion may be necessary if thrombocytopenia is present or if the patient was on antiplatelet therapy 2
Special Considerations for Anticoagulated Patients
- The American Heart Association recommends that for patients on direct factor Xa inhibitors (rivaroxaban, apixaban) or warfarin who develop bleeding after TNK, standard reversal protocols apply: prothrombin complex concentrate (PCC) for warfarin or factor Xa inhibitors, with dosing based on the specific agent and INR if applicable 4
Critical Pitfalls to Avoid
- The European Society of Cardiology warns not to confuse TNK with streptokinase, as streptokinase causes antibodies and hypotension requiring specific management, while TNK does not 1
- The American College of Cardiology advises not to delay supportive care waiting for a "reversal agent", as none exists, and time is critical in managing bleeding complications 2
- The American Heart Association recommends monitoring high-risk patients closely, including elderly patients, those with low body weight, females, and patients with uncontrolled hypertension, as they have a higher bleeding risk 2, 1
Management of Bleeding Complications After Tenecteplase Administration
Patient Risk Factors and Bleeding Complications
- Intracranial hemorrhage occurs in approximately 0.9-1.0% of patients, with risk factors including advanced age, lower weight, female gender, prior cerebrovascular disease, and hypertension on admission, according to the European Heart Journal 5